1SXPD Stock Overview
Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SCHOTT Pharma AG & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €29.70 |
| 52 Week High | €39.60 |
| 52 Week Low | €29.70 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1SXPD | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 1.7% |
| 1Y | n/a | -30.0% | 8.3% |
Return vs Industry: Insufficient data to determine how 1SXPD performed against the UK Life Sciences industry.
Return vs Market: Insufficient data to determine how 1SXPD performed against the UK Market.
Price Volatility
| 1SXPD volatility | |
|---|---|
| 1SXPD Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 1SXPD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 1SXPD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1884 | 4,681 | n/a | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. The company offers prefillable glass or polymer syringes, glass vials, cartridges, and ampoules. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container.
SCHOTT Pharma AG & Co. KGaA Fundamentals Summary
| 1SXPD fundamental statistics | |
|---|---|
| Market cap | €4.10b |
| Earnings (TTM) | €150.41m |
| Revenue (TTM) | €948.56m |
27.3x
P/E Ratio4.3x
P/S RatioIs 1SXPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1SXPD income statement (TTM) | |
|---|---|
| Revenue | €948.56m |
| Cost of Revenue | €624.35m |
| Gross Profit | €324.20m |
| Other Expenses | €173.79m |
| Earnings | €150.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Dec 12, 2024
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 34.18% |
| Net Profit Margin | 15.86% |
| Debt/Equity Ratio | 24.5% |
How did 1SXPD perform over the long term?
See historical performance and comparison